April 11th 2025
Accuracy of data recorded with the GlucoBeam was found to be comparable to standard finger-stick blood glucose tests.
Diabetes: A Primer on New Drug Options
November 1st 2007Over the past 20 years, the treatment armamentarium for diabetes has greatly expanded: 8 different classes of non-insulin drugs and 8 different types of insulin are now available. The newer classes of agents include disaccharidase inhibitors, thiazolidinediones, meglitinides, glucagonlike peptide analogs, and dipeptidyl peptidase IV inhibitors.
Reasons Sought for Racial Disparities in Diabetes and Asthma Outcomes
September 24th 2007ANN ARBOR, Mich. -- Differences in self-management and socioeconomic factors account only in part for the disparities in glycemic control and asthma outcomes between minority and white patients with diabetes and asthma, investigators in two studies found.
EASD: Early Initiation of Insulin Improves Glucose Control in Type 2 Diabetes
September 21st 2007AMSTERDAM -- Adding insulin to oral antidiabetic agents early in the course of disease can help patients achieve better glucose control, but many patients will need a combined insulin regimen, investigators reported.
EASD: Average Blood Glucose Reflects Real Life Glycemia
September 18th 2007AMSTERDAM -- Average blood glucose appears to accurately reflect the daily variations in glycosylated hemoglobin that patients experience, and it may become a new glycemia measure that's easier for patients to grasp than HbA1c.
EASD: DPP-4 Inhibitor Enhances Glycemic Control as Metformin Add-On
September 18th 2007AMSTERDAM -- Patients with poorly controlled type 2 diabetes were four-times more likely to achieve target glycemia levels when metformin therapy was combined with a novel dipetidyl peptidase-4 (DPP-4) inhibitor, reported researchers here.
Study Suggests How Two Diabetes Drugs May Exacerbate Heart Failure
September 6th 2007NEW YORK -- Experiments in mice suggest that the type 2 diabetes drugs rosiglitazone (Avandia) and pioglitazone (Actos) increase uptake of both glucose and triglycerides in cardiac tissue, causing or exacerbating heart failure.
The Dyslipidemia of Type 2 Diabetes: When and How to Treat
September 1st 2007ABSTRACT: Low-density lipoproteins are the most common atherogenic particles in diabetic dyslipidemia; therefore statins, which dramatically reduce low-density lipoprotein (LDL) cholesterol, are first-line therapy for patients with diabetes. These agents produce equivalent relative risk reductions in those with and without diabetes but confer greater absolute risk reduction because of the increased incidence of ischemic cardiovascular events in those with diabetes. The LDL cholesterol goal for patients with diabetes who do not have coronary heart disease is below 100 mg/dL. For secondary prevention, the goal is below 70 mg/dL. High-dose statin therapy may be required to achieve these goals. Fibric acids are a reasonable initial option for patients with triglyceride levels above 200 mg/dL and high-density lipoprotein (HDL) cholesterol levels below 40 mg/dL; in such patients they reduce risk as effectively as statins. Intermediate-release niacin raises HDL cholesterol levels; the effect is enhanced when niacin is combined with a statin.